| Jul 11 |
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
|
| Jul 3 |
Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results
|
| Jun 28 |
Prima BioMed (IMMP) Loses -34.84% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
| Jun 25 |
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer
|
| Jun 5 |
Immutep slips after stock offering
|
| Jun 5 |
Immutep successfully completes institutional placement and institutional component of entitlement offer
|
| Jun 3 |
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
|
| May 29 |
Immutep's (ASX:IMM) investors will be pleased with their notable 73% return over the last five years
|
